PRURIGO NODULARIS
Clinical trials for PRURIGO NODULARIS explained in plain language.
Never miss a new study
Get alerted when new PRURIGO NODULARIS trials appear
Sign up with your email to follow new studies for PRURIGO NODULARIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection shows promise for debilitating skin condition that causes uncontrollable itching
Disease control OngoingThis study is testing whether an injectable medication called rocatinlimab can reduce severe itching and improve skin lesions in adults with prurigo nodularis, a condition causing intensely itchy bumps. Participants will receive either the medication or a placebo injection for 52…
Matched conditions: PRURIGO NODULARIS
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Tracking a skin Drug's Real-World impact on debilitating itch
Disease control OngoingThis study is observing 100 adults with prurigo nodularis, a skin condition causing severe itching and bumps, who are already prescribed the drug dupilumab. The goal is to see how well the drug works in everyday life to control symptoms like itch, pain, and sleep problems over 18…
Matched conditions: PRURIGO NODULARIS
Sponsor: Sanofi • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New Long-Term treatment tested for debilitating skin itch condition
Disease control OngoingThis study is testing the long-term safety and effectiveness of nemolizumab, an injectable medication, for people with prurigo nodularis—a chronic skin condition causing intense itching and raised bumps. It follows 500 participants for up to 3.5 years to see if the treatment cont…
Matched conditions: PRURIGO NODULARIS
Phase: PHASE3 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New shot aims to stop debilitating skin itch
Symptom relief OngoingThis study is testing an investigational drug called barzolvolimab to see if it can safely reduce severe itching and improve skin lesions in adults with prurigo nodularis. About 140 participants will receive either the drug or a placebo via injection every four weeks for 24 weeks…
Matched conditions: PRURIGO NODULARIS
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC